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Abstract
Purpose The objective was to assess the effect of continuous positive airway pressure (CPAP) on symptoms of anxiety and
depression in patients with obstructive sleep apnea (OSA). We hypothesized a decrease in symptoms at follow-up, but that
improvement relied on CPAP adherence.
Methods The sample comprised 468 patients (mean age 55.5 years (SD = 12.0), 72% men) with OSA who received CPAP at a
Norwegian hospital. OSA was diagnosed according to standard respiratory polygraphy. Mean baseline respiratory event index
(REI) was 28.4 (SD = 20.6). Symptoms of anxiety and depression were assessed prior to CPAP treatment and at follow-up after a
median of 20 weeks, range 6–52 weeks, with the Hospital Anxiety and Depression Scale (HADS). Patients were classified as
CPAP adherent (≥ 4 h per night) or non-adherent (< 4 h per night).
Results There was a significant decrease in anxiety scores from baseline (mean = 5.16, SD = 3.94) to follow-up (mean = 4.76, SD
= 3.81), p < 0.001. Similarly, depression scores decreased from baseline (mean = 4.31, SD = 3.66) to follow-up (mean = 3.89, SD
= 3.69), p < 0.001. Cohen’s d (0.19 and 0.18, respectively) indicated small effect sizes. The reduction in anxiety scores did not
depend on CPAP adherence (no interaction effect F(1, 466) = 0.422, p = 0.516), whereas the reduction in depression scores were
seen only in the CPAP adherent group (interaction effect F(1, 466) = 7.738, p = 0.006).
Conclusions We found a decrease in symptoms of anxiety and depression from baseline to follow-up of CPAP treatment. The
improvement in symptoms of depression was depending on CPAP adherence. This underlines the importance of adherence for
optimal effect of CPAP treatment.
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Introduction
Obstructive sleep apnea (OSA) is a common sleep disorder
characterized by breathing pauses during sleep [1]. Typical
symptoms are snoring and excessive daytime sleepiness [2].
OSA can have severe health implications such as increased
risk of diabetes, obesity, cardiovascular diseases, and prema-
ture death [3–5]. OSA is also associated with increased levels
of psychiatric comorbidities, such as anxiety and depression
[1, 6]. Anxiety and depression are widespread public health
challenges and are together with substance use disorders lead-
ing causes of years lived with disability worldwide [7]. In a
review including 55 publications from 1995 to 2006 looking
at anxiety and depression in OSA patients, the prevalence of
anxiety varied from 11 to 70% and the prevalence of depres-
sion varied from 7 to 63% [6]. The large range in prevalence
was related to many factors, including the use of different
mood scales. Furthermore, the review addressed several lim-
itations of the included studies, such as low number of partic-
ipants, validity issues with the mood scales, and different
methods for diagnosing OSA.
Continuous positive airway pressure (CPAP) is the first-
line treatment for OSA, and is indicated for patients with
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moderate and severe OSA or mild OSA with comorbidities
(cardiovascular diseases, cognitive dysfunction, mood disor-
ders, etc.) [8]. CPAP is extremely effective in keeping the
airways open, and thereby reducing the apneas. It has been
shown to reduce cardiovascular risk and is proven to be cost-
effective in patients with moderate and severe OSA [9, 10],
whereas the effect on anxiety and depression remains uncer-
tain. A previous study on the impact of OSA treatment on
depression shows that depression scores in patients with co-
morbid OSA and depression improve with CPAP [11].
Similarly, the review by Saunamäki and Jehkonen reported
that CPAP might improve mood [6]. However, these findings
were inconsistent and the authors called for long-term follow-
up studies to verify the effectiveness. A meta-analysis implies
that the improved scores in anxiety and depression may be
mediated by patients’ expectations and contact with healthcare
providers [12]. A recent systematic review concludes that the
CPAP treatment has good effect on depression, but not anxi-
ety [13]. However, the study included patients with moderate
or severe OSA and coexisting cardiovascular disease only,
thus, the results may not be generalizable to the overall OSA
population. Hence, there is need for prospective studies in
large OSA populations to further elucidate how psychiatric
comorbidities relate to OSA, and whether treating OSA re-
duces the risk and severity of such disorders.
Against this backdrop, the primary objective of the present
study was to assess the effect of CPAP on symptoms of anx-
iety and depression in a large group of patients with OSA
using the validated Hospital Anxiety and Depression Scale
(HADS) [14, 15]. We hypothesized a decrease in HADS
scores at follow-up after about 3 months with CPAP, but that
this improvement depended on CPAP adherence.
Material and methods
The sample comprised 468 patients diagnosed with OSA
and receiving CPAP treatment (AirsenseTM 10 AutosetTM
or S9 AutoSetTM, ResMed Norway AS) at a Norwegian
university hospital between 2011 and 2017. In total, 338
(72%) of the patients were men and 130 (28%) were wom-
en. Mean age was 55.5 ± 12.0 years (range 21–87). OSA
diagnosis was based on standard out-of-center respiratory
polygraphy using a type 3 portable monitor (EmblettaTM or
NOX T3, Resmed Norway AS) as described in previous
publications [16]. Scoring rules were in accordance with
the 2007 American Academy of Sleep Medicine Manual
[17], defining apneas as a reduction of 90% or more of
baseline nasal airflow with a duration of at least 10 s.
Hypopneas were defined as a nasal flow reduction of 30–
90% of baseline, lasting at least 10 s accompanied by an
oxygen desaturation of ≥ 4%. Obstructive sleep apnea was
classified in accordance with the respiratory event index
(REI), which is the number of apneas and hypopneas per
hour of monitoring, i.e., no OSA (REI < 5), mild OSA (REI
5–14.9), moderate OSA (REI 15–29.9), severe OSA (REI ≥
30). In addition, for mild OSA, presence of symptoms or a
relevant comorbidity, such as hypertension or a mood disor-
der, had to be present. Mean baseline REI in the current
sample was 28.4 ± 20.6 (range 5.0–135.2).
Prior to CPAP treatment, the patients completed a ques-
tionnaire including questions about age, sex, marital status,
mental health, and whether they had been diagnosed with
hypertension, diabetes mellitus, myocardial infarction, stroke,
chronic obstructive pulmonary disease, or angina pectoris.
The same questionnaire was completed at follow-up, which
was scheduled after about 3 months. To assess current symp-
toms of anxiety and depression, the patients completed the
validated HADS [15]. The scale consists of 14 separate state-
ments, divided into two seven-item subscales, one for anxiety
(HADS-A) and one for depression (HADS-D), both reflecting
non-vegetative symptoms during the last week. Each state-
ment has four response alternatives, ranging from a healthy
state (0) to maximum symptom severity (3). The composite
HADS score for either anxiety or depression is consequently
ranging from 0 to 21. A score of 8 or higher on each subscale
indicates that the patient may suffer from anxiety or depres-
sion, respectively [14, 15]. At follow-up, patients were cate-
gorized as CPAP adherent or non-adherent, based on their
average CPAP use the last 90 nights as measured by the
CPAP device. Adherence was defined as CPAP use ≥ 4 h
per night [13, 18, 19].
The study was approved by The Regional Committee for
Medical and Health Research Ethics, Health Region West
(REC 2018/337). Written informed consent was obtained
from all patients.
Statistics
The IBM SPSS Statistics, version 25.0 was used for the data
analyses. Follow-up scores for HADSweremissing for 18.6%
(anxiety) and 16.2% (depression) of the cases. These missing
values were replaced using the conservative last observation
carried forward method [20].
Paired-samples t tests were conducted to evaluate the im-
pact of CPAP on the anxiety (HADS-A) and depression
(HADS-D) scores, respectively. In addition, separate analyses
were conducted including only patients with HADS-A ≥ 8
(possible anxiety) and HADS-D ≥ 8 (possible depression) at
baseline. Normality checks were carried out and the assump-
tions met. Furthermore, mixed between-within subjects
ANOVAs (group × time) were conducted in order to explore
the impact of CPAP adherence (adherence vs non-adherence)
and REI severity (REI ≥ 30 vs REI < 30), respectively, on
HADS scores (baseline vs follow-up). Interaction effects were
further explored using the pairwise t tests for simple effects.
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Cohen’s d for paired values was calculated as a measure of
effect size (d = M1−M2/SD pooled), considering d = 0.2 as
small, d = 0.5 as moderate, and d = 0.8 as large effect sizes
[21].Mixed between-within ANOVAswere also conducted in
order to explore the impact of follow-up time (< 20 weeks vs ≥
20 weeks) on HADS scores (baseline vs follow-up). We used
median split to dichotomize the follow-up variable.
Furthermore, mixed between-within ANOVAs were conduct-
ed in order to explore the impact of the comorbid diseases
(e.g., hypertension vs no hypertension) on HADS scores
(baseline vs follow-up). Significance level was set to 0.05
for all analyses.
Results
Descriptive statistics at baseline are presented in Table 1.
Although follow-up was scheduled at around 3 months, the
actual time for follow-up ranged from 6.0 to 51.9 weeks
(mean 23.7 weeks, median 20.0 weeks). This was mostly
due to patients re-scheduling their appointment. Mean CPAP
adherence at follow-up was 4:20 h use per night (range 0:00 to
9:40 h, SD = 2:24).
Overall, there was a statistically significant decrease in both
HADS-A andHADS-D scores from baseline to follow-up, p <
0.001 (Table 2). Cohen’s d for repeated measures (0.19 for
anxiety and 0.18 for depression) indicated small effect sizes.
When the patients with HADS-A ≥ 8 and HADS-D ≥ 8 were
analyzed separately, both groups had a statistically significant
decrease in HADS scores from baseline to follow-up, with
moderate effect sizes (Cohen’s d = 0.50 for anxiety and 0.61
for depression) (Table 2).
Table 3 shows the results from the mixed between-within
subjects ANOVAs conducted to assess the impact of CPAP
adherence on the changes in HADS scores. There was no
significant interaction effects for HADS-A, F(1, 466) =
0.422, p = 0.516. There was a main effect for time, with both
CPAP adherence groups showing a reduction in HADS-A
(anxiety) scores from baseline to follow-up (Table 3). In con-
trast, for symptoms of depression, there was a significant in-
teraction effect, F(1, 466) = 7.738, p = 0.006, indicating that
the reduction in HADS-D scores was larger in the adherent
group than in the non-adherent group (Table 3). Subsequent
analyses of simple effects revealed a significant reduction in
HADS-D scores for the adherent group (p < 0.001, Cohen’s d
= 0.31), whereas the non-adherent group had no reduction in
HADS-D scores (p = 0.823, Cohen’s d = 0.02). There was a
significant main effect of group in both HADS-A and HADS-
D, with higher HADS scores in the non-adherent group than
in the adherent group (p = 0.011 and 0.004, respectively).
Table 4 shows the results from the mixed between-within
subjects ANOVAs conducted to assess the impact of REI
severity on changes in HADS scores. There was no significant
group × time interaction effect for HADS-A, F(1, 466) =
2.408, p = 0.121. Similarly, there was no significant interac-
tion between REI groups and time for HADS-D, F(1, 466) =
0.118, p = 0.732. There was a main effect for time, with both
REI groups showing a reduction in HADS-D scores from
baseline to follow-up (Table 4). Furthermore, there was a sig-
nificant main effect of group in both HADS-A and HADS-D,
with higher HADS scores in the group with REI ≥ 30 than in
the group with REI < 30 (p = 0.014 and 0.027, respectively).
In terms of follow-up time (< 20 weeks vs ≥ 20 weeks),
there was no significant group × time interaction effects for
HADS-A, F(1,466) = 0.080, p = 0.778. Similarly, there was
no significant group × time interaction effects for HADS-D,
F(1,466) = 3.491, p = 0.062. Furthermore, there was no sig-
nificant group × time interaction effects for neither HADS-A
nor HADS-D in terms of being diagnosed with hypertension,
F(1,457) = 0.318, p = 0.573 and F(1,457) = 0.053, p = 0.819,
respectively. Similarly, no such interaction effects were found
for any of the other comorbid diseases (diabetes mellitus,
myocardial infarction, stroke, COPD, or angina pectoris).
Discussion
We found a significant decrease in symptoms of anxiety and
depression at follow-up compared to baseline. Thus, our find-
ings are in agreement with our initial hypothesis of a reduction
in both HADS-A and HADS-D scores at follow-up after
Table 1 Descriptive statistics at baseline among Norwegian patients
with obstructive sleep apnea
Number of patients 468
Sex, males 71.2% (n = 338)
Age (mean ± SD) 55.5 ± 12.0
REI ( mean ± SD) 28.4 ± 20.6
REI ≥ 30 35.7% (n = 167)
HADS-A (mean ± SD) 5.2 ± 4.0
HADS-D (mean ± SD) 4.3 ± 3.7
HADS-A ≥ 8 26.3% (n = 123)
HADS-D ≥ 8 17.5% (n = 82)
Hypertension1 49.9% (n = 229)
Diabetes mellitus1 15.1% (n = 69)
Myocardial infarction1 7.9% (n = 36)
Stroke1 3.4% (n = 15)
COPD1 5.1% (n = 23)
Angina pectoris1 5.5% (n = 24)
SD, standard deviation; REI, respiratory event index; HADS-A, Hospital
Anxiety and Depression Scale-Anxiety subscale (0–21 scale); HADS-D,
Hospital Anxiety and Depression Scale-Depression subscale (0–21
scale); COPD, chronic obstructive pulmonary disease
1 Based on self-report
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CPAP treatment. The second hypothesis was that the im-
provement would be dependent on CPAP adherence. This
was the case for depression, but not for anxiety.
Previous studies investigating the effect of CPAP on
symptoms of anxiety and depression in patients with OSA
have been inconclusive. Some [11, 12] but not all [22] re-
port that treatment with CPAP improves symptoms of anx-
iety and depression. A review reported that depressive
symptoms were reduced in four out of seven studies and
symptoms of anxiety in two out of four studies [6].
However, low number of participants, validity issues with
the different mood scales, and different methods for diag-
nosing OSA were addressed as limitations in these studies.
A recent study reported no change in depression symptoms
measured with Beck Depression Inventory-Fast Screen
(BDI-FS) after 3 months of CPAP use [23]. When measur-
ing with State-Trait Depression Inventory (IDER), however,
the researchers found a statistically significant decrease in
depression symptoms. Furthermore, they reported a signifi-
cant reduction in anxiety-trait symptoms measured with
State-Trait Anxiety Inventory (STAI) [23]. A strength of this
study was using scales adjusted to OSA patients, including
only non-overlapping symptoms of anxiety and depression.
However, the sample comprised only 48 patients, and there
were no present anxiety or depression symptoms of clinical
relevance at baseline, thus, a potential decrease in these
symptoms may not have been properly assessed. The current
findings among 468 patients with OSA support the notion
about reduced HADS scores after CPAP.
Although the overall HADS scores decreased for both
symptoms of anxiety and depression, the improvement was
only depending on CPAP adherence for depression. This find-
ing is in agreement with Zheng et al., which concluded that
CPAP provides a good treatment for depression, but not for
anxiety [13]. The reason for this is unclear, but pathophysio-
logical mechanisms such as apnea-induced sleep fragmenta-
tion, excessive daytime sleepiness, and decreased gray matter
due to hypoxemia may be reversed by CPAP treatment [24,
25], whereas the CPAP may have an anxiety-inducing effect
from the mask application [13].
There was a significant group difference between adherent
and non-adherent patients in terms of higher HADS scores in
the non-adherent group. This is in accordance with previous
studies finding lower adherence to CPAP in patients with
Table 3 Comparison of HADS-A and HADS-D scores at baseline and follow-up between and within adherence groups among 468 Norwegian
patients treated with CPAP for obstructive sleep apnea
Baseline Follow-up Mean difference Effect size t test ANOVA (p value) (group × time)
Mean ± SD Mean ± SD Mean (95% CI) Cohen’s d p Time Group Interaction
HADS-A
Adherenta (n = 283) 4.83 ± 3.85 4.38 ± 3.72 0.45 (0.20–0.69) 0.21 < 0.001 < 0.001 0.011 0.516
Non-adherentb (n = 185) 5.66 ± 4.03 5.35 ± 3.89 0.31 (0.04–0.60) 0.16 0.028
HADS-D
Adherent (n = 283) 4.06 ± 3.57 3.40 ± 3.50 0.66 (0.41–0.91) 0.31 < 0.001 0.002 0.004 0.006
Non-adherent (n = 185) 4.69 ± 3.77 4.65 ± 3.86 0.04 (− 0.34–0.42) 0.02 0.823
aAdherent was defined as using the CPAP ≥ 4 h per night
b Non-adherent was defined as using the CPAP < 4 h per night
HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale-Depression subscale; CPAP,
continuous positive airway pressure; SD, standard deviation; CI, confidence interval
Significant values are shown in italics
Table 2 Comparison of HADS-A
and HADS-D scores at baseline
and follow-up among 468
Norwegian patients treated with
CPAP for obstructive sleep apnea
Baseline Follow-up Mean difference Effect size t test
Mean ± SD Mean ± SD Mean (95% CI) Cohen’s d p
HADS-A, all patients (n = 468) 5.16 ± 3.94 4.76 ± 3.81 0.40 (0.21–0.58) 0.19 < 0.001
HADS-D, all patients (n = 468) 4.31 ± 3.66 3.89 ± 3.69 0.42 (0.20–0.63) 0.18 < 0.001
HADS-A ≥ 8 (n = 123, 26.3%) 10.50 ± 2.50 9.22 ± 3.32 1.28 (0.82–1.73) 0.50 < 0.001
HADS-D ≥ 8 (n = 82, 17.5%) 10.64 ± 2.27 8.84 ± 3.64 1.80 (1.16–2.45) 0.61 < 0.001
HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale (0–21 scale);HADS-D, Hospital Anxiety and
Depression Scale-Depression subscale (0–21 scale); CPAP, continuous positive airway pressure; SD, standard
deviation; CI, confidence interval
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higher HADS scores, both for anxiety and depression [26].
Anxiety and depression may leave the patients unmotivated
or less tolerant to the CPAP therapy, and further studies
should investigate whether treatment of psychiatric comorbid-
ities may enhance adherence to OSA treatment.
As expected, the effect size was larger when patients
with possible anxiety (HADS-A ≥ 8) and depression
(HADS-D ≥ 8) were analyzed separately. As HADS scores
at baseline for the whole group were low for both anxiety
and depression, many patients had a limited potential for
further reductions. Our study suggests that patients with
high HADS scores at baseline will benefit more from
CPAP on their psychiatric comorbidity. However, this ef-
fect could also be due to “regression to the mean” [27],
meaning that patients with high HADS scores at baseline
are more likely to get closer to the mean if measured a
second time, independently of CPAP adherence.
In a cross-sectional study among OSA patients, Bjorvatn
et al. found that symptoms of anxiety and depression were
negatively associated with OSA severity, after adjusting for
relevant confounders such as sex, age, smoking, alcohol con-
sumption, and obesity [28]. In the present study, however,
there was no significant interaction between OSA severity
and time for either HADS-A or HADS-D. This finding indi-
cates that patients might benefit from CPAP in terms of symp-
toms of anxiety and depression regardless of OSA severity.
As expected, we found a clearly higher prevalence of pos-
sible anxiety (26.3%) and depression (17.5%) among these
OSA patients, compared to means of 12.6% for anxiety and
4.4% for depression in the general Norwegian population
[29]. The mean HADS-A and HADS-D scores were compa-
rable to another Norwegian study in OSA patients, where
HADS mean scores for the whole patient group were 5.4 for
anxiety and 4.8 for depression [26].
The psychopathology underlying the association between
OSA and mental disorders is unclear. Previous studies show-
ing a positive association between OSA and anxiety/
depression are mostly cross-sectional, thus, we cannot tell
cause from effect. Furthermore, it is unclear whether depres-
sion is a primary consequence of OSA or if it occurs second-
ary to OSA-related symptoms (e.g., excessive sleepiness, fa-
tigue, sleep problems, irritability) or to other OSA-related fac-
tors such as obesity and cardiovascular diseases [6]. Treating
OSAwith CPAP has proven to be effective on several of these
symptoms [10, 22], and findings in the present study provide
evidence that CPAPmay have a positive impact on symptoms
of anxiety and depression. Hence, in clinics treating patients
with OSA, follow-up consultations provided by trained
healthcare providers are important to ensure CPAP adherence.
However, patients with psychiatric comorbidity should get a
psychiatric evaluation if the treatment of OSA does not result
in mood improvement. For optimal treatment outcomes in
patients with OSA and comorbid psychiatric disorders, treat-
ment of both disorders should be considered [30].
Some strengths and limitations of the present study
should be noted. The relatively large sample size provided
statistical power to the analyses. Another strength was the
use of a well-validated questionnaire for anxiety and depres-
sion. A recent study highlights the need for studies using
valid scales that not include somatic symptoms found in and
caused by OSA [23]. In contrast to most other anxiety and
depression scales, HADS does not include questions about
vegetative symptoms such as sleepiness and fatigue.
Sleepiness and fatigue are usually considered symptoms di-
rectly related to OSA, thus, a scale focusing on non-
vegetative symptoms of anxiety and depression is a strength.
As the HADS questionnaire asks about symptoms during the
last week, it does not provide formal anxiety or depression
Table 4 Comparison of HADS-A and HADS-D scores at baseline and follow-up between and within REI severity groups among 468 Norwegian
patients treated with CPAP for obstructive sleep apnea
Baseline Follow-up Mean difference Effect size t test ANOVA (p value) (group × time)
Mean ± SD Mean ± SD Mean (95% CI) Cohen’s d p Time Group Interaction
HADS-A
REI ≥ 30a (n = 167) 4.49 ± 3.85 4.29 ± 3.79 0.20 (− 0.08–0.48) 0.11 0.166 < 0.001 0.014 0.121
REI < 30b (n = 301) 5.53 ± 3.95 5.02 ± 3.81 0.51 (0.26–0.75) 0.23 < 0.001
HADS-D
REI ≥ 30 (n = 167) 3.86 ± 3.33 3.39 ± 3.49 0.47 (0.13–0.81) 0.21 0.008 < 0.001 0.027 0.732
REI < 30 (n = 301) 4.56 ± 3.81 4.17 ± 3.78 0.39 (0.11–0.67) 0.16 0.006
REI, respiratory event index; HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale-
Depression subscale; CPAP, continuous positive airway pressure; SD, standard deviation; CI, confidence interval
a REI ≥ 30 is defined as severe obstructive sleep apnea
b REI < 30 is defined as mild to moderate obstructive sleep apnea
Significant values are shown in italics
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diagnoses, only an indication of possible cases. We cannot
be sure whether the decrease in HAD scores from baseline
to follow-up was due to CPAP treatment or to the therapeu-
tic effect of meeting trained health care personnel. However,
the reduction in HADS-D scores was only significant among
the patients with CPAP adherence (≥ 4 h/night), which sug-
gests that there was an actual effect of CPAP on symptoms
of depression. A limitation was that we lacked valid infor-
mation on medications for psychiatric conditions which may
pose a confounder to the results. Another limitation was that
OCST commonly underestimates the number of obstructive
respiratory events per hour compared to polysomnography,
as polygraphy monitors the number of apneas/hypopneas per
hour monitoring rather than total sleep time [1]. This is a
diagnostic uncertainty, and we therefore chose to use the
term REI instead of apnea-hypopnea index. Furthermore,
although follow-up was scheduled at 3 months, the time
interval between baseline and follow-up varied considerably.
This was mostly due to patients re-scheduling their appoint-
ment. We excluded patients attending follow-up in less than
1 month and more than 1 year after baseline, and the statis-
tical analyses showed no significant interaction between
follow-up time (< 20 vs ≥ 20 weeks) and decrease in scores
for neither HADS-A nor HADS-D. The CPAP device re-
ports an average use over the last 90 nights. However, we
do not know how many days of use each patient have, and
this was a limitation. Lastly, some patients did not answer
all HADS questions at follow-up. This was handled with
replacing missing values with scores from baseline (inten-
tion-to-treat), which is a conservative procedure that war-
rants caution when interpreting the data. Such missing sub-
stitution may underestimate the effect of CPAP. However,
the decrease in symptoms of anxiety and depression
remained the same when the patients who did not complete
the HADS questionnaire at follow-up were excluded from
the analyses. This further supports the conclusions from the
present study.
In conclusion, we found a decrease in symptoms of anxiety
and depression from baseline to follow-up of CPAP treatment.
There was an interaction between CPAP adherence and re-
duced HADS-D scores from baseline to follow-up, showing
that only patients with CPAP adherence had a reduction in
symptoms of depression. No such interaction was found for
CPAP adherence and HADS-A scores, suggesting that CPAP
may not be responsible for the reduction in anxiety symptoms.
Acknowledgments We are grateful to the nurses, doctors, and the admin-
istrative staff at the Haukeland University Hospital that have made this
research possible by collecting data from the patients.
Authors’ contributions All authors contributed substantially to the
conception/design of the work, or the analysis or interpretation of the
data. Furthermore, all authors drafted or revised the paper, and approved
the final version of the paper.
Funding Open Access funding provided by University of Bergen.
Data availability The authors agree all data and statistical information
essential to this paper will be made available for review if required.
Compliance with ethical standards
Conflicts of interest The authors declare that they have no conflict of
interest.
Ethics approval The study was approved by The Regional Committee
for Medical and Health Research Ethics, Health Region West (REC
2018/337). All procedures performed in the study were in accordance
with the 1964 Helsinki declaration and its later amendments.
Consent to participate Written informed consent was obtained from all
patients.
Consent for publication The participants gave a consent for the results
to be publicated.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. American Academy of Sleep Medicine (2014) International classi-
fication of sleep disorders. American Academy of Sleep Medicine,
Darien, p 383
2. Malhotra A, White DP (2002) Obstructive sleep apnoea. Lancet.
360(9328):237–245
3. Kendzerska T, Mollayeva T, Gershon AS, Leung RS, Hawker G,
Tomlinson G (2014) Untreated obstructive sleep apnea and the risk
for serious long-term adverse outcomes: a systematic review. Sleep
Med Rev 18(1):49–59
4. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras
A et al (2008) Sleep apnea and cardiovascular disease: an American
Heart Association/american College Of Cardiology Foundation
Scientific Statement from the American Heart Association
Council for High Blood Pressure Research Professional Education
Committee, Council on Clinical Cardiology, Stroke Council, and
Council On Cardiovascular Nursing. In collaboration with the
National Heart, Lung, and Blood Institute National Center on
Sleep Disorders Research (National Institutes of Health).
Circulation 118(10):1080–1111
5. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM,
Mohsenin V (2005) Obstructive sleep apnea as a risk factor for
stroke and death. N Engl J Med 353(19):2034–2041
6. Saunamaki T, Jehkonen M (2007) Depression and anxiety in ob-
structive sleep apnea syndrome: a review. Acta Neurol Scand
116(5):277–288
Sleep Breath
7. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ,
Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N,
Burstein R, Murray CJL, Vos T (2013) Global burden of disease
attributable to mental and substance use disorders: findings from
the Global Burden of Disease Study 2010. Lancet. 382(9904):
1575–1586
8. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil
SP et al (2009) Clinical guideline for the evaluation, management
and long-term care of obstructive sleep apnea in adults. J Clin Sleep
Med 5(3):263–276
9. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ
(2006) Continuous positive airways pressure for obstructive sleep
apnoea in adults. Cochrane Database Syst Rev (3):Cd001106
10. Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Launois S, Borel
AL, Levy P, Pepin JL (2015) Impact of obstructive sleep apnea
treatment by continuous positive airway pressure on cardiometabol-
ic biomarkers: a systematic review from sham CPAP randomized
controlled trials. Sleep Med Rev 21:23–38
11. Edwards C, Mukherjee S, Simpson L, Palmer LJ, Almeida OP,
Hillman DR (2015) Depressive symptoms before and after treat-
ment of obstructive sleep apnea in men and women. J Clin Sleep
Med 11(9):1029–1038
12. Gupta MA, Simpson FC, Lyons DC (2016) The effect of treating
obstructive sleep apnea with positive airway pressure on depression
and other subjective symptoms: a systematic review and meta-anal-
ysis. Sleep Med Rev 28:55–68
13. Zheng D, Xu Y, You S, Hackett ML, Woodman RJ, Li Q,
Woodward M, Loffler KA, Rodgers A, Drager LF, Lorenzi-Filho
G, Wang X, Quan WW, Tripathi M, Mediano O, Ou Q, Chen R,
Liu Z, Zhang X, Luo Y, McArdle N, Mukherjee S, McEvoy RD,
Anderson CS (2019) Effects of continuous positive airway pressure
on depression and anxiety symptoms in patients with obstructive
sleep apnoea: results from the sleep apnoea cardiovascular
Endpoint randomised trial and meta-analysis. EClinicalMedicine.
11:89–96
14. Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity
of the hospital anxiety and depression scale. An updated literature
review. J Psychosom Res 52(2):69–77
15. Zigmond AS, Snaith RP (1983) The hospital anxiety and depres-
sion scale. Acta Psychiatr Scand 67(6):361–370
16. Bjorvatn B, Lehmann S, Gulati S, Aurlien H, Pallesen S, Saxvig IW
(2015) Prevalence of excessive sleepiness is higher whereas insom-
nia is lower with greater severity of obstructive sleep apnea. Sleep
Breathing 19(4):1387–1393
17. Iber C, Ancoli-Israel S, Chesson A, Quan S (2007) The AASM
manual for the scoring of sleep and associated events: rules, termi-
nology and technical specifications, 1st edn. American Academy of
Sleep Medicine, Westchester 59 p
18. Povitz M, Bolo CE, Heitman SJ, Tsai WH, Wang J, James MT
(2014) Effect of treatment of obstructive sleep apnea on depressive
symptoms: systematic review and meta-analysis. PLoS Med
11(11):e1001762
19. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V
et al (2017) Association of positive airway pressure with cardiovas-
cular events and death in adults with sleep apnea: a systematic
review and meta-analysis. Jama. 318(2):156–166
20. Singer J, Willett J (2003) Applied longitudinal data analysis:
modeling change and event occurrence
21. Cohen J (1988) Statistical power analysis for the behavioral sci-
ences, 2nd edn. Lawrence Erlbaum Associates, United States of
America
22. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG
(2019) Treatment of adult obstructive sleep apnea with positive
airway pressure: an American Academy of SleepMedicine system-
atic review, meta-analysis, and GRADE assessment. J Clin Sleep
Med 15(2):301–334
23. Carneiro-Barrera A, Amaro-Gahete FJ, Sáez-Roca G, Martín-
Carrasco C, Ruiz JR, Buela-Casal G (2019)Anxiety and depression
in patients with obstructive sleep apnoea before and after continu-
ous positive airway pressure: the ADIPOSA study. J Clin Med
8(12)
24. Wheaton AG, Perry GS, Chapman DP, Croft JB (2012) Sleep dis-
ordered breathing and depression among U.S. adults: National
Health and Nutrition Examination Survey, 2005-2008. Sleep.
35(4):461–467
25. Canessa N, Castronovo V, Cappa SF, Aloia MS, Marelli S, Falini
A, Alemanno F, Ferini-Strambi L (2011) Obstructive sleep apnea:
brain structural changes and neurocognitive function before and
after treatment. Am J Respir Crit Care Med 183(10):1419–1426
26. Kjelsberg FN, Ruud EA, Stavem K (2005) Predictors of symptoms
of anxiety and depression in obstructive sleep apnea. Sleep Med
6(4):341–346
27. Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the
mean: what it is and how to deal with it. Int J Epidemiol 34(1):215–
220
28. Bjorvatn B, Rajakulendren N, Lehmann S, Pallesen S (2018)
Increased severity of obstructive sleep apnea is associated with less
anxiety and depression. J Sleep Res 27(6):e12647
29. Oyane NM, Bjelland I, Pallesen S, Holsten F, Bjorvatn B (2008)
Seasonality is associated with anxiety and depression: the
Hordaland health study. J Affect Disord 105(1-3):147–155
30. Gupta MA, Simpson FC (2015) Obstructive sleep apnea and psy-
chiatric disorders: a systematic review. J Clin Sleep Med 11(2):
165–175
Comments
This is a prospective cohort studywith larger sample size is its advantage;
this study shown that the improvement in symptoms of depression was
depending onCPAP adherence, which provides the benefits of CPAP and
the importance of improving compliance with CPAP treatment.
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